2 - Is the data (presumably anonymized) made publicly available, so that others can dispute the meaning?
That was the initial plan, yes! Beltran (my co-founder at GB) is worried that will result in either HIPPA issues or something like this, so I'm ultimately unsure. Putting structures in place so the science is right the first time seems better.
The privacy issue here is interesting.
It makes sense to guarantee anonymity. Participants recruited personally by company founders may be otherwise unwilling to report honestly (for example). For health related studies, privacy is an issue for insurance reasons, etc.
However, for follow-up studies, it seems important to keep earlier records including personally identifiable information so as to prevent repeatedly sampling from the same population.
That would imply that your organization/system needs to have a data management system for securely storing the p...
I'm a LW reader, two time CFAR alumnus, and rationalist entrepreneur.
Today I want to talk about something insidious: marketing studies.
Until recently I considered studies of this nature merely unfortunate, funny even. However, my recent experiences have caused me to realize the situation is much more serious than this. Product studies are the public's most frequent interaction with science. By tolerating (or worse, expecting) shitty science in commerce, we are undermining the public's perception of science as a whole.
The good news is this appears fixable. I think we can change how startups perform their studies immediately, and use that success to progressively expand.
Product studies have three features that break the assumptions of traditional science: (1) few if any follow up studies will be performed, (2) the scientists are in a position of moral hazard, and (3) the corporation seeking the study is in a position of moral hazard (for example, the filing cabinet bias becomes more of a "filing cabinet exploit" if you have low morals and the budget to perform 20 studies).
I believe we can address points 1 and 2 directly, and overcome point 3 by appealing to greed.
Here's what I'm proposing: we create a webapp that acts as a high quality (though less flexible) alternative to a Contract Research Organization. Since it's a webapp, the cost of doing these less flexible studies will approach the cost of the raw product to be tested. For most web companies, that's $0.
If we spend the time to design the standard protocols well, it's quite plausible any studies done using this webapp will be in the top 1% in terms of scientific rigor.
With the cost low, and the quality high, such a system might become the startup equivalent of citation needed. Once we have a significant number of startups using the system, and as we add support for more experiment types, we will hopefully attract progressively larger corporations.
Is anyone interested in helping? I will personally write the webapp and pay for the security audit if we can reach quorum on the initial protocols.
Companies who have expressed interested in using such a system if we build it:
(I sent out my inquiries at 10pm yesterday, and every one of these companies got back to me by 3am. I don't believe "startups love this idea" is an overstatement.)
So the question is: how do we do this right?
Here are some initial features we should consider:
Any placebos used in the studies must be available for purchase as long as the results are used in advertising, allowing for trivial study replication.
Significant contributors will receive:
I'm hoping that if a system like this catches on, we can get an "effective startups" movement going :)
So how do we do this right?